U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market Size, Share, Growth Analysis, By Drug Class Analysis(Calcimimetics, Vitamin D Analogues, Phosphate Binders.), By Distribution Channels(Hospital & Retail Pharmacies, Online Channel, Others), By Region - Industry Forecast 2025-2032

U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market size was valued at USD 5.4 billion in 2019 and is poised to grow from USD 5.75 billion in 2023 to USD 9.52 billion by 2031, growing at a CAGR of 6.5% during the forecast period (2024-2031).

Due to its strong pharmaceutical portfolio and important strategic choices, Amgen Inc. dominates the secondary hyperparathyroidism therapy (SHPT) industry, holding 40 %. Sensipar (Cinacalcet), a popular medicine from Amgen, is used to treat SHPT. Due to the patent expiration of many treatments, generic manufacturers have just begun to come on the market. Players in the market include organizations like Teva Pharmaceutical Industries Ltd., Abbvie, and Sandoz, among others. Growing generic manufacturer competition is also anticipated to fuel SHPT market expansion during the anticipated time frame. 'Amgen Inc. (US)', 'F. Hoffmann-La Roche AG', 'AbbVie Inc.', 'Pfizer Inc.', 'Sanofi S.A.', 'GlaxoSmithKline plc', 'Novartis International AG', 'Teva Pharmaceutical Industries Ltd.', 'Kyowa Kirin Co., Ltd.', 'Bayer AG', 'AstraZeneca plc', 'Baxter International Inc.', 'Fresenius Medical Care AG & Co. KGaA', 'Merck & Co., Inc.', 'Eli Lilly and Company', 'Johnson & Johnson', 'Ipsen S.A.', 'Amneal Pharmaceuticals LLC', 'Impax Laboratories, Inc.', 'Mylan N.V.'

Vitamin D deficiency coexists with SHPT development. According to OPKO Health, Inc., more than 97 percent of ESRD patients exhibit signs of vitamin D deficiency, which is a key sign that SHPT is developing in the patient. Therefore, it is anticipated that the SHPT treatment market in the U.S. will be driven by the rise in the prevalence of chronic illnesses brought on by a sedentary lifestyle.

The management plan for SHPT has been enhanced as medical professionals and clinical specialists have become more aware of the condition. The early detection and evaluation of secondary hyperparathyroidism for mineral metabolism in CKD and ESRD would have a beneficial effect on the market growth for treatments for this condition. During the projection period, it is anticipated that the market would develop more quickly due to the decrease in issues related to the management of SHPT.

Geographically, the West, Midwest, South, and Northeast areas make up the U.S. SHPT therapy market. The South region brought in USD 1.93 billion in revenue and is expected to take the lead in the US market over the next several years. The South region's dominance can be attributed to the existence of a large number of dialysis facilities and the strategic positioning of top dialysis clinic networks like Fresenius Care, DaVita, etc. in the area. Additionally, due to the high incidence of older people with kidney disorders, the southern region of the United States has the highest prevalence of secondary hyperparathyroidism.

U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market size was valued at USD 5.75 Billion in 2023 and is poised to grow from USD 6.12 Billion in 2024 to USD 10.14 Billion by 2032, growing at a CAGR of 6.5% during the forecast period (2025-2032).

Due to its strong pharmaceutical portfolio and important strategic choices, Amgen Inc. dominates the secondary hyperparathyroidism therapy (SHPT) industry, holding 40 %. Sensipar (Cinacalcet), a popular medicine from Amgen, is used to treat SHPT. Due to the patent expiration of many treatments, generic manufacturers have just begun to come on the market. Players in the market include organizations like Teva Pharmaceutical Industries Ltd., Abbvie, and Sandoz, among others. Growing generic manufacturer competition is also anticipated to fuel SHPT market expansion during the anticipated time frame. 'Amgen Inc. (US)', 'F. Hoffmann-La Roche AG', 'AbbVie Inc.', 'Pfizer Inc.', 'Sanofi S.A.', 'GlaxoSmithKline plc', 'Novartis International AG', 'Teva Pharmaceutical Industries Ltd.', 'Kyowa Kirin Co., Ltd.', 'Bayer AG', 'AstraZeneca plc', 'Baxter International Inc.', 'Fresenius Medical Care AG & Co. KGaA', 'Merck & Co., Inc.', 'Eli Lilly and Company', 'Johnson & Johnson', 'Ipsen S.A.', 'Amneal Pharmaceuticals LLC', 'Impax Laboratories, Inc.', 'Mylan N.V.'

Vitamin D deficiency coexists with SHPT development. According to OPKO Health, Inc., more than 97 percent of ESRD patients exhibit signs of vitamin D deficiency, which is a key sign that SHPT is developing in the patient. Therefore, it is anticipated that the SHPT treatment market in the U.S. will be driven by the rise in the prevalence of chronic illnesses brought on by a sedentary lifestyle.

The management plan for SHPT has been enhanced as medical professionals and clinical specialists have become more aware of the condition. The early detection and evaluation of secondary hyperparathyroidism for mineral metabolism in CKD and ESRD would have a beneficial effect on the market growth for treatments for this condition. During the projection period, it is anticipated that the market would develop more quickly due to the decrease in issues related to the management of SHPT.

Geographically, the West, Midwest, South, and Northeast areas make up the U.S. SHPT therapy market. The South region brought in USD 1.93 billion in revenue and is expected to take the lead in the US market over the next several years. The South region's dominance can be attributed to the existence of a large number of dialysis facilities and the strategic positioning of top dialysis clinic networks like Fresenius Care, DaVita, etc. in the area. Additionally, due to the high incidence of older people with kidney disorders, the southern region of the United States has the highest prevalence of secondary hyperparathyroidism.